13F Holdings
中文EN

TVTX Travere Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1438533 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY49.4%
TTM net income YoY-37.2%
TTM EPS YoY-26.2%
Revenue 3-yr CAGR71.3%
Net income 3-yr CAGR—

Margins

Gross margin98.5%
Operating margin-20.5%
Net margin-18.7%
FCF margin—
EBITDA margin-12.4%

Returns

ROE-252.7%
ROA-17.5%
ROIC (approx.)—
Asset turnover0.94x

Leverage & solvency

Liabilities / assets97.3%
Debt / equity0.00x
Current ratio3.00x
Interest coverage-15.05x

Cash quality & payout

Operating cash flow / net income-1.54x
Accruals ratio-44.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$490.73M$233.18M$145.24M$109.46M$131.84M
Cost of revenue$10.34M$7.74M$11.45M$4.42M$3.82M
Gross profit$480.39M$225.43M$133.79M$105.04M$128.02M
R&D expense$206.01M$217.50M$244.99M$227.33M$201.16M
SG&A expense$337.20M$264.12M$265.54M$197.52M$126.28M
Operating income-$62.82M-$323.83M-$388.14M-$319.81M-$199.43M
Interest expense$10.75M$11.18M$11.33M$11.01M$19.70M
Pretax income-$49.27M-$320.51M-$376.11M-$331.15M-$216.88M
Income tax$988,000$120,000$223,000$313,000$409,000
Net income-$25.55M-$321.55M-$111.40M-$278.48M-$180.09M
EBITDA-$2.08M-$280.27M-$349.61M-$299.09M-$186.68M
EPS (basic)-0.29-4.08-1.50-4.37-3.01
EPS (diluted)-0.29-4.08-1.50-4.37-3.01
Weighted avg. shares (diluted)89.21M78.89M74.27M63.76M59.83M
Balance sheet
Cash & equivalents$93.03M$58.53M$58.18M$61.69M$165.75M
Short-term investments$145.38M—$248.64M$285.53M$262.19M
Receivables$80.13M$27.12M$21.18M$16.65M$15.91M
Inventory$36.16M$41.86M$9.41M$4.52M$7.31M
Current assets$437.56M$416.70M$616.77M$486.44M$582.83M
PP&E, net$4.02M$5.34M$7.48M$9.05M$11.11M
Goodwill—$800,000$800,000$800,000$900,000
Intangibles$113.87M$103.97M$104.44M$97.07M$148.44M
Total assets$605.19M$594.12M$788.91M$672.59M$776.63M
Current liabilities$159.90M$200.75M$177.91M$142.16M$124.09M
Total liabilities$490.36M$535.05M$588.10M$629.73M$474.52M
Shareholders' equity$114.83M$59.08M$200.81M$42.85M$302.11M
Shares outstanding90.92M87.45M75.37M64.29M62.49M
Cash flow statement
Operating cash flow$37.78M-$237.47M-$280.02M-$186.29M-$14.79M
Capital expenditure——$668,000$191,000$5.10M
Free cash flow——-$280.69M-$186.48M-$19.89M
Investing cash flow$27.89M$99.33M$55.78M-$32.55M-$137.62M
Financing cash flow-$33.47M$139.42M$218.75M$117.57M$231.68M
Depreciation & amortization$60.74M$43.55M$38.53M$20.72M$12.75M
Stock-based compensation$44.87M$36.91M$44.25M$38.14M$29.57M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.